glucagon-like peptide-1 agonists marketglp 1 agonist market shareglp-1 agonist salesglp 1 agonist marketThe is currently ruled by two names — Eli Lilly and Novo Nordisk — who together hold close to 94% of global share. That kind of concentration makes tracking almost a two-company exercise today, but the picture is shifting fast. Upcoming patent expiries, biosimilar entrants, and a widening pipeline mean the story of the next decade will look very different from 2024's near-duopoly. For anyone running analysis, this transition period is exactly where the interesting competitive movement will happen.

Sizing the Opportunity: GLP-1 Market Size and Growth

glp 1 market sizeglp-1 market analysisglp-1 market analytics dataEvery estimate now has to account for obesity, not just diabetes. With roughly 32 million US adults living with type 2 diabetes and an estimated 120 million adults and children meeting obesity criteria, the community has had to repeatedly revise addressable-population assumptions upward. This is the backdrop for most models projecting an 11-year forecast window through 2036 — a horizon long enough to capture both patent cliffs and next-generation launches.

Semaglutide, Tirzepatide, and the Broader GLP-1 Analogue Landscape

glp-1 analogues marketoral glp-1/glucagon dual agonist development 2025Within the , semaglutide (Ozempic, Rybelsus, Wegovy) remains the volume leader at roughly 58% share, while tirzepatide (Mounjaro, Zepbound) — a dual GIP/GLP-1 agonist — posted 2025 sales of USD 36.51 billion combined, with Zepbound alone growing about 44% year-over-year into Q2 2026. Eli Lilly's oral entrant Foundayo (orforglipron), approved in April 2026, has meanwhile reset expectations for the conversation by removing food and water restrictions typical of earlier oral incretins.

Who's Leading: GLP-1 Companies and Pipeline Assets

leading glp-1 drug market companiesleading pharma manufacturers advancing glp-1 agonists for obesity clinical developmentglp-1 therapeutic analyticsA current list runs through Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Zealand Pharma, and AstraZeneca. Among , Boehringer Ingelheim's survodutide (BI 456906) stands out after Phase III data showed up to 34% visceral fat reduction and 63.1% liver fat reduction in obesity patients. Novo Nordisk's CagriSema — a fixed-dose cagrilintide/semaglutide combination — and Eli Lilly's retatrutide round out the assets most coverage watches closely, with retatrutide's Phase III package now complete for obesity, sleep apnea, and knee osteoarthritis submissions.

Competitive Monitoring and Indirect Competitor Analysis

evaluate the pharmaceuticals company ozempic on glp-1 efficacy / effectivenessevaluate the diabetes & obesity pharmaceuticals company trulicity on indirect competitor monitoringevaluate the pharmaceuticals company byetta on amgen and glp-1For teams asked to , the relevant benchmarks now include not just glycemic control but cardiovascular event reduction and kidney disease progression, both part of Ozempic's expanded label. Similarly, to , or to , analysts increasingly weigh legacy GLP-1 agents against newer dual- and multi-agonist mechanisms rather than against each other alone.

What's Next in the GLP-1 Pipeline

approved glp-1 receptor agonists list 2026glp-1 gip glucagon amylin mc4r pyy peptide drugs pipeline 2019-2026oral glp-1 glucagon dual agonist development 2025which pharmaceutical companies have the largest market share in the prescription glp-1 receptor agonist weight loss drug spaceBeyond the current , the reflects a broader industry push into multi-receptor agonism. This is the core of most and research questions — the next leg of growth depends less on new molecules targeting GLP-1 alone and more on combination biology that layers in glucagon, GIP, or amylin pathways.

Market Access, Reimbursement, and Long-Term Outlook

beste glp-1 receptoragonister producenteremerging commercial opportunities in pharmaceuticals for peptide therapeutics and glp1 medicines in the a$ marketglp-1 agonists industryPricing remains the single biggest lever in discussions worldwide, with programs like Novo Nordisk's patient-assistance initiatives illustrating how access strategy is now inseparable from commercial strategy. As continue to surface, expect competition to increasingly hinge on convenience (oral vs. injectable), tolerability, and breadth of approved indications rather than glycemic efficacy alone — a trend that will define the through 2036.

Latest Reports Offered by Delveinsight

seizure detection device pd4 inhibitors pharma consulting what is mld what is the peppermint new drugs for depression cd40l liver cirrhosis clinical trial 2026 update press release digital pathology ai news anti inflammatory for colitis progeria life expectancy nieman pick what is biosensor winrevair cost car-t market ai product research tools health wellness pain relief 2024 pharmaceutical consultant water sparkling isbrella examples of mobile health applications,,,,,,,,,,,,,,,,,,,

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

GLP-1 Receptor Agonists: Understanding Market Growth, Competition, and Innovation Through 2036

Pricing remains the single biggest lever in beste glp-1 receptoragonister producenter discussions worldwide, with programs like Novo Nordisk's patient-assistanc